Clinical Trial Search

Primary: Number of Participants With HBV DNA Level < 2.1 log10 Copies/mL at Week 24 — 8; 12 participants

Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events(SAEs, AEs Leading to Withdrawal, and Death — 1; 1; 3; 24 Partipants

Primary: Adjusted Mean Change in HbA1c Levels — -0.52; -0.65; -0.59; -0.30 Percent — p=0.0106

Primary: Change From Baseline Trough in 24-hour Weighted Mean FEV1 on Treatment Day 84 — 0.117; 0.095 Liters — p=0.201

Primary: Percentage of Subjects Reporting At Least One Treatment-emergent Adverse Event (TEAE) During The Study Period — 70.8 percentage of participants

Primary: PASI 75 at Week 12 — 48.3; 65.2 Percentage of participants — p=<0.001

Primary: Number of Participants Who Tested Positive for Anti-denosumab Antibodies at Month 6 — 0; 0 Participants

Primary: Number of Participants With One or More Adjudicated Events of Bleeding (Major or Non-major) With Onset Within 24 Hours After Study Drug Administration — 17; 24…

Primary: Mean Percent Change From Baseline in Lumbar Spine BMD at Month 6 — 4.10; 0.89 Percent change — p=<0.0001

Primary: Efficacy: the Pearl Index (Number of Pregnancies Per 100 Woman-years) in the Primary Evaluable Population (18-35) — 22.4 pregnancies per 100 woman years

Primary: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE) During the Treatment Period — 139; 134; 73; 3 participants

Primary: Overall Survival at the Time of Primary Analysis — 12.2; 10.5 Months — p=0.3492

Primary: Number of Subjects With Pain Relief at 2 Hours From Time of First Dose — 136; 231 participants

Primary: Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis. — -11.3; -14.6; -14.4 Units on a…

Primary: Mean Change From Baseline in Serum HBV DNA Level at Week 24 — -4.63; -4.50 log10 copies/milliliter (copies/mL) — p=<0.0001